Related Experiment Video
Updated: Jan 28, 2026

Preparation and Applications of Organotypic Thymic Slice Cultures
Published on: August 6, 2016
A case of thymic carcinoma harboring an FGFR3 S249C mutation with durable disease control on lenvatinib
Noriko Bando1, Hirokazu Ogino1, Kojin Murakami1
1Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15, Kuramoto-cho, Tokushima, 770- 8503 Japan.
Abstract:
Thymic carcinoma is a rare and aggressive malignancy with limited treatment options, resulting in a poor prognosis. Lenvatinib, a small-molecule inhibitor targeting multiple receptor tyrosine kinases, including fibroblast growth factor receptors (FGFRs), has been approved for thymic carcinoma that progresses following platinum-based chemotherapy. However, the identification of predictive biomarkers for its efficacy remains an unmet medical need. We herein present a case of 67-year-old man with advanced thymic carcinoma who was treated with carboplatin plus paclitaxel as first-line therapy. Lenvatinib, administered as second-line therapy, achieved a durable disease control that was maintained for over 20 months-exceeding the previously reported median progression-free survival. Comprehensive genomic profiling (CGP) using the FoundationOne® CDx assay identified an oncogenic FGFR3 S249C mutation. The case, together with supporting literature, suggests the potential role of FGFR3 mutations as therapeutic targets in thymic carcinoma. Furthermore, the presence of oncogenic mutations in lenvatinib-targeted genes may serve as predictive biomarkers for durable disease control. Given the limited availability of methods to detect oncogenic mutations, including FGFR3, in patients with thymic carcinoma, early implementation of CGP testing-even in the frontline setting-may be warranted in the future.
Insights
This case study highlights a patient with advanced thymic carcinoma who achieved long-term disease control with lenvatinib. An FGFR3 mutation was identified, suggesting its potential as a predictive biomarker for targeted therapy.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Thymic carcinoma is a rare, aggressive cancer with poor prognosis and limited treatment options.
- Lenvatinib is approved for thymic carcinoma post-chemotherapy, but predictive biomarkers are needed.
- Fibroblast growth factor receptors (FGFRs) are targeted by lenvatinib.
Purpose of the Study:
- To report a case of advanced thymic carcinoma treated with lenvatinib.
- To investigate potential predictive biomarkers for lenvatinib efficacy in thymic carcinoma.
- To explore the role of FGFR3 mutations in thymic carcinoma treatment.
Main Methods:
- A 67-year-old male patient with advanced thymic carcinoma received first-line carboplatin plus paclitaxel.
- Second-line therapy involved lenvatinib, a multi-targeted tyrosine kinase inhibitor.
- Comprehensive genomic profiling (CGP) was performed using the FoundationOne® CDx assay.
Main Results:
- Lenvatinib provided durable disease control for over 20 months, exceeding median progression-free survival.
- CGP identified an oncogenic FGFR3 S249C mutation.
- The findings suggest FGFR3 mutations may predict response to lenvatinib.
Conclusions:
- FGFR3 mutations may represent actionable therapeutic targets in thymic carcinoma.
- Oncogenic mutations in lenvatinib-targeted genes could serve as predictive biomarkers.
- Early CGP testing, including for FGFR3 mutations, may be beneficial for thymic carcinoma patients.
More Related Videos
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Brick Durability, Strength, and Appearance
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms

